重组人干扰素治疗疱疹性咽炎123例疗效分析.docVIP

重组人干扰素治疗疱疹性咽炎123例疗效分析 f two groups were treated with conventional prevention of infection and symptomatic treatment. The 123 patients of treatment group were also given recombinant human interferon (1 μg/kg, im. 1 times /d, for 3 days). 107 patiets of control group were treated with ribavirin ［10 mg/(kg?d), iv.1 times/d, for 3 days］.The clinical symptoms and signs, radiological and laboratory data of these patients were retrospectively evaluated. Results In the treatment group, the overall response rate was 98.38%, the median time of thermal process was (3.74± 2.3)d, the median period of throat congestion and herpes was (4.64± 2.3)d, and length of stay (6.44± 2.1)d. In the control group, the total efficiency was 80.37%, the median time of thermal process was (4.32± 2.6)d, throat congestion and the median time of herpes was (6.84± 2.3)d, and length of stay (9.3± 1.1)d. Cooling time, the period of herpes and length of stay of patients in the treatment group was significantly better than that of patients in the control group (P0.05). Conclusion Recombinant human interferon in the treatment of pediatic herpes pharyngitis can rapidly improve the condition of patients and efficacy, induce the length of stay. 　　【Key words】 Herpes pharyngitis；Recombinant human interferon；Efficacy 　　 疱疹性咽炎是由柯萨奇A组病毒感染所致的、小儿急性上呼吸道感染的一种特殊类型，好发于夏秋季［1］；主要治疗为应用抗病毒药物(病毒唑)及对症处理，预防并发症；但既往治疗疗效长、副作用大［2］，使得本组考虑采用重组人干扰素治疗疱疹性咽炎，现将观察结果报告如下。 　　1 资料与方法 　　1.1 一般资料 2008年3月至2011年3月间经门诊收治的疱疹性咽炎确诊病例230例，男117例，女113例，年龄2~15岁(平均年龄7.91岁)；并采用随机数字表法将患儿随机分为两组。治疗组123例，其中男67例、女56例，平均病程(4.64±2.3)d；对照组107例，男50例、女57 例，平均病程(6.84±2.3)d。 　　1.2 诊断标准 确诊的疱疹性咽炎患儿依据《儿科学》诊断标准［3］。 　　1.3 纳入标准 符合入组年龄；突然出现发热、咽疼、拒咽、流涎；咽充血，咽弓、软腭、悬雍垂的黏膜见2个~10个灰白 　　色疱疹，直径1～3 mm，周围有红晕；病变局限于咽峡部而未及口腔前部，齿龈及颊黏膜部未见；局部淋巴结不肿大；末梢血白细胞计数正常或略低，无异常淋巴细胞。两组患儿年龄、性别、发病时间、临床表现、血白细胞及C反应蛋白方面情况无显著差异，具有可比性。 　　1.4 排除标准 年龄2岁、15岁者；伴有原发性心血管、肝、肾及造血系统和精神、神经系统疾病者；对治疗药物过敏者。 　　1.5 治疗方法 两组常规预防感染及对症治疗，治疗组123例患儿给予重组人干扰素1 μg/(kg?次)，1次/d，肌内注射，连续3 d；对照组107例患儿给予病毒唑10 mg/(kg?d)静脉滴注，1次/d，